Whitehawk Therapeutics faces a precarious outlook as its revenue stream has completely evaporated, dropping to zero by 2025Q4, while R&D expenditures remain unsustainably high at $19.0 million for the same period. The company's reliance on non-recurring milest...
Price trend, volume and key moving averages
Trailing total returns as of 10/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$0.20+32.4% vs -$0.30 | — vs $350,000 |
Q2 2026 May 7, 2026 | -$0.32+11.1% vs -$0.36 | — vs — |
Q2 2026 Mar 12, 2026 | -$0.34+38.2% vs -$0.55 | — vs — |
Q4 2025 Nov 6, 2025 | -$0.26+49.0% vs -$0.51 | — vs $25M |
Shares of Whitehawk Therapeutics, Inc. (NASDAQ: WHWK - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the eight brokerages that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have issued a buy recommendation
Whitehawk Therapeutics, Inc. (WHWK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026PR Newswire
PTK7 Expression Remained Stable Following Standard-of-Care Therapies, Supporting Its Relevance as a Target in Second- or Later-Line EGFR NSCLC Findings Reinforce the Scientific Rationale for HWK-007, Whitehawk's Next-Generation PTK7-Directed ADC Currently in Phase 1 Development MORRISTOWN, N.J., Sept. 13, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved antibody drug conjugate (ADC) cancer treatments, today announced the presentation of two real-world analyses supporting protein tyrosine kinase 7 (PTK7) as a durable and clinically relevant ADC target in patients with pretreated, EGFR wild-type non-small cell lung cancer (NSCLC).
Benchmark WHWK against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Whitehawk Therapeutics Inc (WHWK)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.70 | $182.97M | -11.21 | -72.5% | -288.26% | -21.82% | — | |
| $19.95 | $3.42B | 8.71 | 11.87% | 33.42% | 32.39% | — | |
| $179.25 | $9.22B | -48.71 | 65.55% | -24.68% | -255.6% | — | |
| $20.50 | $1.51B | 6.21 | 18.52% | 80.56% | 30.03% | — | |
| $295.51 | $8.24B | -21.92 | -100% | — | -34.15% | — | |
| $2.91 | $50.21M | -2.17 | — | -691.81% | — | — |
Whitehawk Therapeutics Inc (WHWK) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Whitehawk Therapeutics Inc (WHWK) SEC filings — annual & quarterly reports (10-K, 10-Q)
Mar 12, 2026·SEC
Nov 6, 2025·SEC
Aug 7, 2025·SEC
Get notified when WHWK posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Whitehawk Therapeutics Inc (WHWK) stock FAQ — growth, dividends, profitability & financials explained
Whitehawk Therapeutics Inc (WHWK) reported $7.1M in revenue for fiscal year 2025. This represents a 854% increase from $0.7M in 2019.
Whitehawk Therapeutics Inc (WHWK) saw revenue decline by 72.5% over the past year.
Whitehawk Therapeutics Inc (WHWK) reported a net loss of $79.8M for fiscal year 2025.
Whitehawk Therapeutics Inc (WHWK) has a return on equity (ROE) of -21.8%. Negative ROE indicates the company is unprofitable.
Whitehawk Therapeutics Inc (WHWK) had negative free cash flow of $69.3M in fiscal year 2025, likely due to heavy capital investments.
